The Food and Drug Administration approved expanded treatment uses for the anti-inflammatory drug llaris, developed by Basel, Switzerland-based Novartis.
Llaris, developed by Basel, Switzerland-based Novartis, was first approved in 2009 for the treatment of cryopyrin-associated periodic syndromes and active systemic juvenile idiopathic arthritis. The medication can now be used to treat three more rare auto-inflammatory diseases: Tumor necrosis factor receptor associated periodic syndrome, hyperimmunoglobulin D syndrome /mevalonate kinase deficiency and familial Mediterranean fever.
"For the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life," said Badrul Chowdhury, MD, PhD, director of the division of pulmonary, allergy and rheumatology products in FDA's Center for Drug Evaluation and Research.
More articles on supply chain:
Big-box distribution centers on the rise: 4 things to know
UPS testing drones for emergency medical supply deliveries
FDA fast tracks malaria vaccine